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Abstract
Carnitine is essential for mitochondrial oxidation of long-chain fatty acids. Peripheral cells rely on plasma transport of
carnitine which is taken up by an active mechanism in the plasma membrane. This project investigated the plasma membrane
bound carnitine carrier in cultured S49 lymphoma cells. We investigated wild-type cells and two mutant cells lines showing
deficient activity of adenylyl cyclase, cyc3 lacking and H21a containing a deficient GsK. Plasma membranes derived from
cyc3 cells displayed six times more carnitine binding sites and a 1.35 times faster uptake rate than plasma membranes from
wild-type cells. In vitro mixing of plasma membranes from cyc3 and wild-type cells transferred a factor reducing the number
of expected carnitine binding sites by about 30%. Cyclic AMP could not substitute for wild-type membranes as the inhibitor
of carnitine binding to plasma membranes derived from cyc3 cells. Cholera toxin induced ADP-ribosylation of GsK causing
activation of GsK present in wild-type but not in cyc3 cells, further reducing carnitine uptake and carnitine binding to plasma
membranes. Our findings thus supported the notion that GsK by a mechanism not involving cyclic AMP inhibited cellular
uptake of carnitine by reducing the number of available carnitine binding sites in plasma membranes. ß 1998 Elsevier
Science B.V. All rights reserved.
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1. Introduction
Carnitine is a low molecular weight compound es-
sential for oxidation of long-chain fatty acids in the
mitochondria [1]. Peripheral tissues depend on plas-
ma transport of carnitine and maintain a 10^2000-
fold carnitine concentration gradient over their plas-
ma membrane [2^4]. An active carnitine uptake
mechanism has been demonstrated in several tissues
[2^10]. Reports suggest a negative in£uence on car-
rier-mediated carnitine uptake by LiCl presumably
by interfering with the transmembrane sodium gra-
dient [11], by cycloheximide inhibiting protein syn-
thesis [12], by both SH-blocking or SH-binding re-
agents [11], and by diphtheria toxin [13]. Starvation
[14] and prednisolone [15] seem to facilitate cellular
uptake of carnitine. A cardiac carnitine binding pro-
tein has been identi¢ed in rat ventricular homoge-
nates [16]. In a previous report [17] we have charac-
terized binding of carnitine to plasma membranes
derived from murine S49 lymphoma cells. Carnitine
binding to plasma membranes was demonstrated to
occur through a mechanism requiring ATP and mag-
nesium ions and inhibited by genistein, a protein
tyrosine kinase inhibitor [17].
We report here ¢ndings suggesting the GsK-protein
to be a major negative regulator of carnitine cellular
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uptake and carnitine membrane binding in S49 lym-
phoma cells through a mechanism not involving cy-
clic AMP.
2. Materials and methods
2.1. Cell culture and membrane preparation
S49 lymphoma cells were cultivated in suspension
culture and harvested as previously described [18].
Plasma membranes were puri¢ed by a discontinuous
sucrose gradient and characterized using enzyme
markers as reported [17]. The fraction between the
23% and 34% sucrose layer was denoted plasma
membrane enriched fraction (PMx) where the su⁄x
x indicates the cell type wt, cyc3 or H21a respectively
fractionated.
2.2. [3H]L-Carnitine binding to isolated PM
The radioligand binding assay was carried out [17]
in 50 Wl of a 20 mM Tris-HCl bu¡er, pH 7.4, con-
taining 1 mM EDTA, 120 mM NaCl supplemented
with 1 mM MgCl2, 3H-labeled 0.4 WM^1 mM L-car-
nitine (4.4 million dpm), and various agents at indi-
cated concentrations. Incubation was initiated by ad-
dition of 20 Wg pre-warmed PM and stopped by snap
freezing in liquid N2. Non-speci¢c carnitine binding
was minimized by pelleting the membranes before
the vacuum ¢ltration through ultracentrifugation of
the barely thawed incubation mixture. Tubes were
thawed for 3 min, centrifuged 100 000Ug at 4‡C
for 1 h. The supernatant was discarded and the pellet
resuspended in 750 Wl binding assay bu¡er, ¢ltered
(BA 85, Schleicher and Schuell) and washed twice
under reduced pressure at 4‡C. The ¢lters were dried
and counted in 7.5 ml scintillation £uid (Ready Pro-
tein, Beckman). Non-speci¢c binding of carnitine to
membranes was de¢ned by inclusion of 20 mM un-
labeled carnitine in the incubation bu¡er. Equilib-
rium binding experiments were evaluated by non-lin-
ear regression analysis [19].
2.3. Cellular uptake of carnitine
Uptake in S49 lymphoma cells was performed in
500 Wl of DMEM supplemented with 10% dialyzed
horse serum, 0.4^200 WM L-carnitine and 74 kBq
[3H]L-carnitine and various agents at indicated con-
centrations as previously reported [9,17].
2.4. General analytical procedures
Succinate-cytochrome c reductase activity [20,21],
carnitine palmitoyltransferase 1 [22,23], ouabain
binding sites [24], L-adrenoceptors (speci¢c
[125I]cyanopindolol binding), GsK concentration, the
Al3/Mg2/F3-stimulated activity of the cyc3 recon-
stituted adenylyl cyclase [25^28], and carnitine con-
centration [29,30] were determined as described.
Treatment of cells and PM by cholera toxin were
undertaken as published [31]. The actual ADP-ribo-
sylation of GsK induced by cholera toxin was checked
Table 1
Characterization of plasma membranes derived from wild-type, cyc3, and H21a S49 lymphoma cells
Wild-type cyc3 H21a
Ouabain binding sites (fmol/mg) 721 þ 64 641 þ 82 593 þ 112
L-Adrenoceptor binding (fmol/mg) 133 þ 21 168 þ 18 159 þ 24
GsK concentration (pmol/mg) 38.6 þ 6.9 6 0.8 þ 0.6* 32.3 þ 8.1
Reconstituted adenylyl cyclase activity (pmol/mg/min) 321 þ 89 12 þ 8* 19 þ 11*
Carnitine palmitoyl transferase 1 (nmol/mg/min) 0.5 þ 0.1 0.2 þ 0.1 0.2 þ 0.1
Succinate-cytochrome c reductase (nmol/mg/min) 0.6 þ 0.2 0.6 þ 0.1 0.5 þ 0.2
S49 lymphoma cells were subfractionated as described in Section 2 and the interphase fraction between 23% and 34% sucrose layers
was used for assay for various marker enzyme activities. The membrane homogenate from wild-type cells applied on the gradient con-
tained 43.1 þ 12.9 fmol/mg L-adrenoceptors, 13.7 þ 3.1 pmol/mg GsK, and 62.2 þ 9.2 nmol/mg/min succinate-cytochrome c reductase.
The corresponding membrane homogenates from cyc3 and H21a cells contained 6 0.3 þ 0.4 and 12.1 þ 4.2 pmol/mg of GsK, respec-
tively and 58.8 þ 7.9 and 64.1 þ 10.3 nmol/mg/min succinate-cytochrome c reductase activity, respectively.
*Statistically signi¢cant (n = 8; P6 0.001) di¡erences in GsK concentration (PMcyc3 ) and in adenylyl cyclase (PMcycÿ, PMH21a) reconsti-
tuted activity versus PMwt.
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using radiolabeled NAD followed by gel electro-
phoresis and autoradiography as described [31]. Pro-
tein concentration was determined by the Bio-Rad
microassay using bovine albumin as protein standard
[32]. Results were expressed as mean þ S.D. (n = num-
ber of experiments).
3. Results
3.1. Binding of L-carnitine to PM
PM were prepared as reported [17] from S49 lym-
phoma cells. PM contained (Table 1) as judged by
assay of the mitochondrial marker enzymes, carnitine
palmitoyl transferase and succinate-cytochrome c re-
ductase, negligible mitochondrial contamination
while still retaining high concentrations of plasma
membrane markers (ouabain binding sites, L-adreno-
ceptors). Two mutant S49 lymphoma cell lines hav-
ing a defect adenylyl cyclase were utilized, the cyc3
mutant lacking the stimulatory G-protein, GsK, and
the H21a strain having a de¢cient GsK activity [33].
Both mutants were checked by assay of GsK concen-
tration and activity (Table 1).
Carnitine binding to PM was assessed using triti-
ated carnitine as reported [17]. PMwt bound 475
pmol/mg membrane protein (Fig. 1) distributed on
two binding sites displaying di¡erent a⁄nities (Table
2). PMcyc3 (Fig. 1) and PMH21a (data not shown)
bound about sixfold more carnitine than PMwt ; all
binding sites displayed a single a⁄nity (Table 2). The
di¡erence in number of binding sites between PM
from wild-type and mutant cell lines was decreased
but nonetheless existed even when ATP was omitted
from the incubation bu¡er (data not shown). These
data suggested that the di¡erence between PM from
mutant and wild-type cells did not depend on the
previously reported regulatory mechanism of carni-
tine binding operating through a protein tyrosine
kinase.
The hypothesis that plasma membranes from wild-
type cells contain a factor inhibiting carnitine mem-
brane binding was investigated by experiments mix-
ing PMcyc and PMwt (Table 3). Addition of PMwt to
Fig. 1. Dose-response curves for carnitine binding to PM de-
rived from wild-type and cyc3 cells. PM derived from wild-type
(inset, E) and cyc3 (a) cells were incubated for 20 min at indi-
cated concentrations of [3H]L-carnitine in the absence (E, a)
and presence (F, b) of dithiothreitol-activated cholera toxin and
NAD as described in Section 2. The number of carnitine bind-
ing sites and the corresponding dissociation constants were cal-
culated [19] by non-linear regression analysis (Table 2). Each
curve is based on a representative experiment run in triplicate.
Table 2
Carnitine equilibrium binding to PM derived from wild-type, cyc3, and H21a S49 lymphoma cells
BH (pmol/mg) KH (WM) BL (pmol/mg) KL (WM)
Wild-type cells 27 þ 8 1.2 þ 0.9 448* þ 51 21.3 þ 5.8
Wild-type cells+cholera toxin 47 þ 16 2.1 þ 1.2 313* þ 34 29.5 þ 6.8
cyc3 cells ^ ^ 2999 þ 132 28.9 þ 3.6
cyc3 cells+cholera toxin ^ ^ 3030 þ 103 27.2 þ 1.9
H21a cells ^ ^ 3012 þ 141 25.9 þ 3.1
PM derived from wild-type, cyc3, and H21a cells were incubated for 20 min as described in Fig. 1 at di¡erent concentrations of
[3H]L-carnitine in the absence and presence of dithiothreitol-activated cholera toxin and NAD as described in Section 2. The number
of carnitine binding sites (BH, H = high a⁄nity sites, and BL, L = low a⁄nity sites; pmol/mg membrane protein) and the corresponding
dissociation constants (KH and KL ; WM) were calculated [19] by non-linear regression analysis.
*Values di¡er in a statistically signi¢cant way (n = 6, P6 0.001).
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PMcyc3 prior to assaying carnitine binding to mem-
branes reduced the number of available carnitine
binding sites, not only below the expected sum of
the respective membrane contributions, but to a level
of about 30% less than in PMcyc3 alone. Addition of
100 WM cyclic AMP slightly attenuated carnitine
binding in PMcyc3 but could not replace PMwt as
the inhibitory factor (Table 3).
3.2. Cellular carnitine uptake in S49 lymphoma cells
Carrier-mediated uptake of carnitine was saturable
and followed Michaelis-Menten kinetics. Q-Butyrobe-
taine, a carnitine analogue, almost completely
blocked the carrier-mediated carnitine uptake when
added in tenfold excess and passive di¡usion was
estimated [34] at 50 WM carnitine to be 21 þ 4
amol/cell/h. Cellular uptake of carnitine was signi¢-
cantly higher (P6 0.001) in cyc3 cells than in wild-
type S49 lymphoma cells (Fig. 2), carrier-mediated
maximal carnitine uptake rate in wild-type S49 lym-
phoma cells was determined to be 173 þ 6 amol/cell/h
(n = 8) whereas the maximal uptake rate in the cyc3
mutant S49 cell line was estimated to be 237 þ 7
amol/cell/h (n = 4). The Km values were 21.9 þ 2.1
and 23.9 þ 1.9 WM for wild-type and cyc3 cells re-
spectively, i.e. they did not di¡er signi¢cantly be-
tween the two cell types.
The carnitine concentration in media supple-
mented with 10% horse serum, i.e. under standard
cell culture conditions, is approx. 2 WM. Determina-
tion of the intracellular concentration of carnitine in
S49 lymphoma cells showed the cyc3 mutant cells to
maintain a higher intracellular concentration of L-
carnitine than wild-type cells. The intracellular con-
centration of carnitine was determined after 72 h at
2.1 WM carnitine in the utilized cell culture media to
70 þ 4 versus 53 þ 5 amol/cell for cyc3 and wild-type
cells respectively (n = 6, P6 0.01). The volume of S49
lymphoma cells was determined to be 203 þ 31 £
(n = 8). The nuclei were estimated by area calculation
in photographs to constitute about 62.3 þ 8.5%
(n = 8) of total cellular volume leaving the cytoplasm
Table 3
Inhibition of carnitine binding to PMcyc3 by PMwt
No PMcycÿ 20 Wg PMcycÿ 20+20 Wg PMcycÿ
No PMwt 132 102 178 þ 3112 174 098 þ 5809
20 Wg PMwt 10 631 þ 1231 78 911 þ 2652* nd
20+20 Wg PMwt 20 447 þ 1983 nd nd
Carnitine equilibrium binding experiments were performed utilizing membranes derived from wild-type (PMwt), and cyc3 (PMcycÿ)
S49 lymphoma cells. Carnitine binding assay was performed using respective membrane type or a mixture of both membrane types
under conditions maximizing carnitine binding (200 WM carnitine, 20 min). No detergents were added. Results are expressed as
counts/min. Predicted value for the mixture of 20 Wg membranes of each type (marked with *) were 112 809 cpm; i.e. the actual bind-
ing obtained was statistically signi¢cantly (P6 0.01, n = 5) reduced by 30%. Addition of 100 WM cyclic AMP reduced binding by
3.6 þ 1.1%. nd, not done.
Fig. 2. Cellular carnitine uptake in untreated (E, a) and cholera
toxin pretreated wild-type and cyc3 S49 lymphoma cells. Wild-
type (F) and cyc3 (b) cells were preincubated in cell culture me-
dia supplemented with 10 Wg/ml cholera toxin for 1 h and then
incubated at indicated concentrations of radiolabeled carnitine
and analyzed for labeled carnitine as described in Section 2.
Wild-type (E) and cyc3 (a) cells preincubated in cell culture
media without cholera toxin were used as control. Non-satura-
ble passive di¡usion was subtracted from total cellular uptake
of L-carnitine. Each curve is based on a representative experi-
ment run in quadruplicate.
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a volume of 73 þ 19 £. The intracellular concentra-
tion of carnitine in the cytoplasm (we could not de-
tect any carnitine in the nucleus) was thus calculated
to be 959 þ 56 and 726 þ 70 WM in cyc3 and wild-
type cells respectively, i.e. the cyc3 cells maintained
an almost 500-fold concentration gradient over the
plasma membrane. The rate of speci¢c carrier-medi-
ated uptake of carnitine at 2.1 WM carnitine in the
media was determined to be 4.9 þ 0.8 and 8.9 þ 0.7
amol/cell/h (n = 4, P6 0.001) in wild-type and cyc3
cells, respectively.
3.3. E¡ect of cholera toxin on carnitine membrane
binding and cellular uptake
Cholera toxin speci¢cally ADP-ribosylates the
GsK-protein trapping the GsK in its activated GTP-
liganded state. PM were ADP-ribosylated by prein-
cubation for 5 min prior to the carnitine equilibrium
binding experiments in carnitine binding bu¡er sup-
plemented with dithiothreitol-activated cholera toxin
and NAD. Activated cholera toxin induced ADP-
ribosylation of GsK in PM from wild-type cells as
veri¢ed using radiolabeled NAD and subjecting
the incubation mixture to SDS gel electrophoresis
followed by autoradiography (data not shown). The
presence of 50 Wg/ml of activated cholera toxin atten-
uated the number of carnitine binding sites in PMwt
but left carnitine binding to PMcyc3 unperturbed
(Fig. 2). The high a⁄nity site for carnitine binding
usually observable in PMwt remained detectable in
the presence of activated cholera toxin (Table 2).
Unactivated cholera toxin did not in£uence carnitine
binding.
Intact S49 lymphoma cells were preincubated for
1 h in ordinary cell culture media supplemented with
10 Wg/ml of cholera toxin, resuspended in fresh me-
dia without cholera toxin, and cellular carrier-medi-
ated carnitine uptake was measured at various carni-
tine concentrations. Only cells remaining viable after
the cholera toxin treatment were utilized. Pretreat-
ment by cholera toxin decreased statistically signi¢-
cantly the uptake rate of carnitine in wild-type
(P6 0.001) but not in cyc3 cells (Fig. 2); speci¢c
uptake rates were determined to be 133 þ 8 and
248 þ 7 amol/cell/h (n = 4), respectively. The Km val-
ues were not signi¢cantly altered by the cholera toxin
treatment.
4. Discussion
S49 lymphoma cells are of widespread use in signal
transduction studies because of the availability of
mutant cell lines displaying a defect adenylyl cyclase.
Two of these mutant cell lines, the cyc3 and H21a
strains, were here found to display a quite substantial
increase in both carnitine binding to PM and in cel-
lular carnitine uptake rates as compared to wild-type
cells. PM from the mutant cells lines displayed not
only a sixfold increase in number of carnitine binding
sites but also showed di¡erent binding characteristics
with only one type of carnitine binding sites. Experi-
ments utilizing mixing of PM from wild-type and
cyc3 cells demonstrated the presence of a transfer-
able factor in PMwt that induced a substantial inhib-
ition of carnitine membrane binding in PMcyc3. The
reduction induced by adding PMwt actually reduced
the number of available carnitine binding sites to a
level below the number of sites present in PMcyc3,
i.e. the di¡erence between the two di¡erent mem-
brane types could not solely be quantitative but
must at least be qualitative. Cyclic AMP, based on
the adenylyl cyclase defect in the mutant cells lines
was an obvious factor to investigate. Direct addition
of cyclic AMP to the PM induced a small reduction
in the number of carnitine binding sites in PM but
could not account for the di¡erence between the two
cell lines or the substantial inhibition observed when
mixing the two membrane types. The absence of GsK-
protein in membranes from cyc3 cells may further be
argued through its highly hydrophobic nature to
cause some non-speci¢c disruption of membranes
changing carnitine membrane binding characteristics.
This objection was refuted by the observation that
the H21a mutant, having a de¢cient GsK-protein,
showed carnitine membrane characteristics virtually
identical to membranes from cyc3 cells. The time
frame, the absence of detergents, and the extent of
the inhibitory e¡ect made GsK, based on experience
from of reconstitution of adenylyl cyclase by mem-
brane extracts [28], a rather unlikely candidate for
the role as a transferable inhibitor.
Although the cyc3 mutant cell line lacks the GsK-
protein [25,33], other hitherto unknown di¡erences
might be of importance for the transmembranous
transport of carnitine. Cholera toxin induces ADP-
ribosylation of GsK enhancing the activity of Gs by
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blocking the intrinsic GTPase activity in GsK and
thus leaving GsK in its GTP-liganded state [33]. Pre-
incubation of S49 lymphoma cells in cell culture me-
dia containing cholera toxin, attenuated the carnitine
uptake rate in wild-type cells but left the uptake rate
in cyc3 cells unperturbed, thus supporting the notion
of a mechanistic connection between the GsK activity
and the cellular uptake mechanisms for carnitine.
Membrane experiments utilizing cholera toxin
showed that ADP-ribosylation of GsK induced a de-
crease in the number of membrane binding sites for
carnitine suggesting that increased GsK activity in-
duced inhibition of the carnitine carrier system.
Cholera toxin did not a¡ect carnitine binding to
PMcyc3 or the cellular carnitine uptake rate in cyc3
cells indicating that the observed e¡ects in wild-type
cells were due to ADP-ribosylation of GsK rather
than non-speci¢c toxic mechanisms. The observed
di¡erences between cyc3 and wild-type cells re-
mained irrespective of the presence of ATP, indicat-
ing that the di¡erence did not involve mechanisms
related to the previously reported protein tyrosine
kinase [17].
We thus conclude that GsK seems to be a major
negative regulator of the carnitine carrier by a mech-
anism not operating through adenylyl cyclase.
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